Cargando…

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality

Lin et al. recently did a network meta-analysis based on cardiovascular (CV) outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and those of glucagon-like peptide-1 receptor agonists (GLP1RAs). Due to the absence of CVOTs directly comparing SGLT2is with GLP1RAs, Lin et al....

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Mei, Wei, Xu-Bin, Wei, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688798/
https://www.ncbi.nlm.nih.gov/pubmed/34950720
http://dx.doi.org/10.3389/fcvm.2021.791311
_version_ 1784618422215114752
author Qiu, Mei
Wei, Xu-Bin
Wei, Wei
author_facet Qiu, Mei
Wei, Xu-Bin
Wei, Wei
author_sort Qiu, Mei
collection PubMed
description Lin et al. recently did a network meta-analysis based on cardiovascular (CV) outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and those of glucagon-like peptide-1 receptor agonists (GLP1RAs). Due to the absence of CVOTs directly comparing SGLT2is with GLP1RAs, Lin et al.'s network meta-analysis identified the indirect evidence that SGLT2is vs. GLP1RAs reduced hospitalization for heart failure (HHF) but did not reduce CV death and all-cause mortality (ACM) in patients with type 2 diabetes (T2D). We did another meta-analysis incorporating those CV outcome cohort studies directly comparing SGLT2is with GLP1RAs, and identified that SGLT2is vs. GLP1RAs were significantly associated with the lower risks of not only HHF but also CV death and ACM. These findings may suggest that SGLT2is should be considered over GLP1RAs in terms of preventing CV and all-cause death and HHF in T2D patients.
format Online
Article
Text
id pubmed-8688798
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86887982021-12-22 SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality Qiu, Mei Wei, Xu-Bin Wei, Wei Front Cardiovasc Med Cardiovascular Medicine Lin et al. recently did a network meta-analysis based on cardiovascular (CV) outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and those of glucagon-like peptide-1 receptor agonists (GLP1RAs). Due to the absence of CVOTs directly comparing SGLT2is with GLP1RAs, Lin et al.'s network meta-analysis identified the indirect evidence that SGLT2is vs. GLP1RAs reduced hospitalization for heart failure (HHF) but did not reduce CV death and all-cause mortality (ACM) in patients with type 2 diabetes (T2D). We did another meta-analysis incorporating those CV outcome cohort studies directly comparing SGLT2is with GLP1RAs, and identified that SGLT2is vs. GLP1RAs were significantly associated with the lower risks of not only HHF but also CV death and ACM. These findings may suggest that SGLT2is should be considered over GLP1RAs in terms of preventing CV and all-cause death and HHF in T2D patients. Frontiers Media S.A. 2021-12-07 /pmc/articles/PMC8688798/ /pubmed/34950720 http://dx.doi.org/10.3389/fcvm.2021.791311 Text en Copyright © 2021 Qiu, Wei and Wei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Qiu, Mei
Wei, Xu-Bin
Wei, Wei
SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
title SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
title_full SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
title_fullStr SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
title_full_unstemmed SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
title_short SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
title_sort sglt2is vs. glp1ras reduce cardiovascular and all-cause mortality
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688798/
https://www.ncbi.nlm.nih.gov/pubmed/34950720
http://dx.doi.org/10.3389/fcvm.2021.791311
work_keys_str_mv AT qiumei sglt2isvsglp1rasreducecardiovascularandallcausemortality
AT weixubin sglt2isvsglp1rasreducecardiovascularandallcausemortality
AT weiwei sglt2isvsglp1rasreducecardiovascularandallcausemortality